153 related articles for article (PubMed ID: 35508792)
1. Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity.
Chierigo F; Borghesi M; Würnschimmel C; Flammia RS; Horlemann B; Sorce G; Hoeh B; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Montorsi F; Chun FKH; Shariat SF; Mantica G; Suardi N; Terrone C; Karakiewicz PI
Int Urol Nephrol; 2022 Jul; 54(7):1521-1527. PubMed ID: 35508792
[TBL] [Abstract][Full Text] [Related]
2. Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups.
Würnschimmel C; Wenzel M; Collà Ruvolo C; Nocera L; Tian Z; Saad F; Briganti A; Shariat SF; Mirone V; Chun FK; Tilki D; Graefen M; Karakiewicz PI
Int J Urol; 2021 Aug; 28(8):862-869. PubMed ID: 33993551
[TBL] [Abstract][Full Text] [Related]
3. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities.
Würnschimmel C; Wenzel M; Collà Ruvolo C; Nocera L; Tian Z; Saad F; Briganti A; Shariat SF; Mandel P; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
World J Urol; 2021 Oct; 39(10):3781-3787. PubMed ID: 33978812
[TBL] [Abstract][Full Text] [Related]
4. Race/Ethnicity Determines Life Expectancy in Surgically Treated T1aN0M0 Renal Cell Carcinoma Patients.
Würnschimmel C; Collà Ruvolo C; Nocera L; Wenzel M; Tian Z; Saad F; Briganti A; Shariat SF; Mirone V; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
Eur Urol Focus; 2022 Jan; 8(1):191-199. PubMed ID: 33610487
[TBL] [Abstract][Full Text] [Related]
5. Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables.
Würnschimmel C; Nocera L; Wenzel M; Ruvolo CC; Tian Z; Saad F; Briganti A; Shariat SF; Mirone V; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
J Racial Ethn Health Disparities; 2023 Apr; 10(2):708-717. PubMed ID: 35182370
[TBL] [Abstract][Full Text] [Related]
6. Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups.
Hoeh B; Würnschimmel C; Flammia RS; Horlemann B; Sorce G; Chierigo F; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Terrone C; Shariat SF; Tilki D; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
Prostate; 2022 May; 82(6):676-686. PubMed ID: 35188981
[TBL] [Abstract][Full Text] [Related]
7. Differences in overall survival between clear cell metastatic renal cell carcinoma patients versus population-based controls according to race/ethnicity in the United States.
Cano Garcia C; Nimer N; Piccinelli ML; Tappero S; Panunzio A; Barletta F; Incesu RB; Tian Z; Saad F; Kapoor A; Briganti A; Terrone C; Shariat SF; Tilki D; Antonelli A; De Cobelli O; Kluth LA; Becker A; Chun FKH; Karakiewicz PI
Ann Epidemiol; 2023 Mar; 79():65-70. PubMed ID: 36640918
[TBL] [Abstract][Full Text] [Related]
8. The effect of race on stage at presentation and survival in upper tract urothelial carcinoma.
Collà Ruvolo C; Wenzel M; Nocera L; Würnschimmel C; Tian Z; Shariat SF; Saad F; Longo N; Imbimbo C; Briganti A; Mirone V; Karakiewicz PI
Urol Oncol; 2021 Nov; 39(11):788.e7-788.e13. PubMed ID: 34330651
[TBL] [Abstract][Full Text] [Related]
9. Contemporary vs historical survival rates in metastatic clear cell renal carcinoma according to race/ethnicity.
Sorce G; Hoeh B; Hohenhorst L; Panunzio A; Tappero S; Nimer N; Tian Z; Larcher A; Capitanio U; Tilki D; Terrone C; Chun FKH; Antonelli A; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2022 Dec; 40(12):2971-2978. PubMed ID: 36222885
[TBL] [Abstract][Full Text] [Related]
10. African American vs Caucasian race/ethnicity in adrenocortical carcinoma patients.
Panunzio A; Tappero S; Hohenhorst L; Cano Garcia C; Piccinelli M; Barletta F; Tian Z; Tafuri A; Briganti A; De Cobelli O; Chun FKH; Tilki D; Terrone C; Saad F; Shariat SF; Bourdeau I; Cerruto MA; Antonelli A; Karakiewicz PI
Endocr Relat Cancer; 2023 Jul; 30(7):. PubMed ID: 37043366
[TBL] [Abstract][Full Text] [Related]
11. The effect of race/ethnicity on histological subtype distribution, stage at presentation and cancer specific survival in urethral cancer.
Wenzel M; Deuker M; Stolzenbach F; Nocera L; Collà Ruvolo C; Tian Z; Shariat SF; Saad F; Briganti A; Kluth LA; Chun FKH; Karakiewicz PI
Urol Oncol; 2021 Jun; 39(6):369.e9-369.e17. PubMed ID: 33309509
[TBL] [Abstract][Full Text] [Related]
12. Other-cause mortality and access to care in metastatic renal cell carcinoma according to race/ethnicity.
Sorce G; Hoeh B; Hohenhorst L; Panunzio A; Tappero S; Tian Z; Larcher A; Capitanio U; Tilki D; Terrone C; Chun FKH; Antonelli A; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
Urol Oncol; 2022 Nov; 40(11):493.e9-493.e16. PubMed ID: 35907705
[TBL] [Abstract][Full Text] [Related]
13. The effect of race/ethnicity on cancer-specific mortality after salvage radical prostatectomy.
Wenzel M; Würnschimmel C; Nocera L; Colla Ruvolo C; Hoeh B; Tian Z; Shariat SF; Saad F; Briganti A; Graefen M; Preisser F; Becker A; Mandel P; Chun FKH; Karakiewicz PI
Front Oncol; 2022; 12():874945. PubMed ID: 36059656
[TBL] [Abstract][Full Text] [Related]
14. Differences in overall survival of T2N0M0 bladder cancer patients vs. population-based controls according to treatment modalities.
Cano Garcia C; Piccinelli ML; Tappero S; Panunzio A; Barletta F; Incesu RB; Tian Z; Saad F; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Antonelli A; De Cobelli O; Kosiba M; Banek S; Kluth LA; Chun FKH; Karakiewicz PI
Int Urol Nephrol; 2023 May; 55(5):1117-1123. PubMed ID: 36813873
[TBL] [Abstract][Full Text] [Related]
15. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.
Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2022 Jan; 40(1):103-110. PubMed ID: 34436637
[TBL] [Abstract][Full Text] [Related]
16. Hispanic
Panunzio A; Tappero S; Garcia CC; Piccinelli M; Barletta F; Incesu RB; Tian Z; Tafuri A; Tilki D; Briganti A; DE Cobelli O; Chun FKH; Terrone C; Saad F; Shariat SF; Bourdeau I; Cerruto MA; Antonelli A; Karakiewicz PI
Anticancer Res; 2022 Nov; 42(11):5579-5585. PubMed ID: 36288855
[TBL] [Abstract][Full Text] [Related]
17. The effect of race/ethnicity on cancer-specific mortality after trimodal therapy.
de Angelis M; Baudo A; Siech C; Jannello LMI; Di Bello F; Goyal JA; Tian Z; Longo N; de Cobelli O; Chun FKH; Saad F; Shariat SF; Carmignani L; Gandaglia G; Moschini M; Montorsi F; Briganti A; Karakiewicz PI
J Racial Ethn Health Disparities; 2024 Mar; ():. PubMed ID: 38509444
[TBL] [Abstract][Full Text] [Related]
18. Survival differences in non-seminoma testis cancer patients according to race/ethnicity.
Incesu RB; Barletta F; Tappero S; Piccinelli ML; Garcia CC; Morra S; Scheipner L; Tian Z; Saad F; Shariat SF; Ahyai S; Longo N; Chun FKH; de Cobelli O; Terrone C; Briganti A; Tilki D; Graefen M; Karakiewicz PI
Cancer Epidemiol; 2024 Apr; 89():102538. PubMed ID: 38377946
[TBL] [Abstract][Full Text] [Related]
19. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.
Shavers VL; Brown ML; Potosky AL; Klabunde CN; Davis WW; Moul JW; Fahey A
J Gen Intern Med; 2004 Feb; 19(2):146-55. PubMed ID: 15009794
[TBL] [Abstract][Full Text] [Related]
20. Differences in Stage of Cancer at Diagnosis, Treatment, and Survival by Race and Ethnicity Among Leading Cancer Types.
Zhang C; Zhang C; Wang Q; Li Z; Lin J; Wang H
JAMA Netw Open; 2020 Apr; 3(4):e202950. PubMed ID: 32267515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
